Precision medicine directed therapy enabling long-term survival in medulloblastoma: a case report - Takeaways - MDSpire

Precision medicine directed therapy enabling long-term survival in medulloblastoma: a case report

  • By

  • Laura Vazquez

  • Jonathan Lerch

  • Divya Gandra

  • Abigail Moore

  • Jessica Lincoln

  • Abhinav B. Nagulapally

  • Suzanne Treadway

  • Krishnamoorthy Thamburaj

  • Valerie Brown

  • Giselle Saulnier Sholler

  • July 14, 2026

Share

  • 1

    Medulloblastoma (MB) is the most common malignant brain tumor in children, with subgroup-SHH associated with poor prognosis and high metastatic potential.

  • 2

    Current treatment for MB includes surgery, radiation, chemotherapy, and autologous stem cell transplant, but relapsed patients have a 10-30% long-term survival rate.

  • 3

    A 6-year-old male with SHH MB underwent surgery and high-dose chemotherapy, but relapsed nine months later, leading to enrollment in a clinical trial.

  • 4

    Genomic sequencing and a molecular tumor board recommended targeted therapies, resulting in a complete tumor response and long-term survival for the patient.

  • 5

    The study highlights the potential of precision medicine in treating relapsed MB by tailoring therapies based on individual tumor molecular profiles.

Original Source(s)

Precision medicine directed therapy enabling long-term survival in medulloblastoma: a case report

  • by Laura Vazquez, Jonathan Lerch, Divya Gandra, Abigail Moore, Jessica Lincoln, Abhinav B. Nagulapally, Suzanne Treadway, Krishnamoorthy Thamburaj, Valerie Brown, Giselle Saulnier Sholler

  • July 14, 2026

Related Content

Surgery confers survival benefit in De Novo metastatic soft tissue sarcoma patients with low Ki67 or low total lesion glycolysis: a combined PET/CT and clinicopathological analysis

Editorial: Molecular pathways and signaling molecules in cancer therapy: advances and innovations

Nutritional interventions in cancer management: a comprehensive scoping review